Rat Xenograft Models

Rat xenograft models address constraints that are anatomical and physiological rather than immunological. The mouse is the default xenograft host for sound reasons of cost, availability, and the depth of available immunodeficient backgrounds. Its size, however, imposes limits that matter for certain classes of study, and where those limits bind, no amount of careful mouse work will substitute.

Altogen Labs conducts rat oncology studies in an IACUC-regulated facility, and supports integration of serial pharmacokinetic sampling with efficacy endpoints in the same animal, which is the design advantage that usually justifies selecting the species. Model availability, host background, and study configuration are confirmed per program at the design stage. To discuss whether a rat study is warranted, request a quote.

Where the rat is the better host

Serial blood sampling is the most common reason. Total blood volume in the rat permits repeated sampling from the same animal across a full pharmacokinetic time course. In the mouse, a comparable schedule generally requires composite sampling across multiple animals, which introduces inter-animal variance into the exposure profile and increases the number of animals required.

Physiological scaling is the second. Several parameters relevant to exposure modeling are closer to human in the rat, and the larger sample volumes available support more demanding bioanalytical methods. Where exposure-response relationships are central to the question, this is a substantive rather than marginal advantage, and is why regulatory toxicology programs frequently include a rodent species other than the mouse.

Surgical tractability is the third. Orthotopic implantation, catheterization, and other surgical procedures are easier at rat scale, with better access and lower procedural loss.

Tissue yield is the fourth. Larger tumors and organs provide more material for parallel endpoints, allowing histology, molecular analysis, protein work, and archival storage from a single animal where a mouse study would require separate cohorts for each.

Finally, immunodeficient rat backgrounds have been developed and validated for human tumor oncology and support cell lines and patient-derived material that establish poorly in conventional murine hosts.

Study design

Design follows the same principles as murine xenograft work: implantation at a defined cell or fragment dose, randomization stratified by baseline tumor volume once tumors reach a defined size, and pre-specified primary and secondary endpoints. Dose levels, administration volumes, and sampling schedules are set for the species rather than scaled informally from a mouse protocol, since allometric scaling of dose is not a substitute for species-appropriate tolerability assessment.

Endpoints include tumor volume, tumor growth inhibition, survival, and tolerability. Integration of serial pharmacokinetic and pharmacodynamic sampling with efficacy endpoints in the same animal is the principal design advantage of the platform.

Applied examples

Exposure-response in one animal. A tumor-bearing cohort is dosed and sampled across a full concentration time course, with tumor response followed in the same animals, so that exposure and efficacy are related within subjects rather than across separately dosed groups.

Tissue-rich endpoint panel. A single study supports tumor histopathology, protein analysis, transcript analysis, and archived frozen tissue from each animal, where the equivalent mouse study would have required three cohorts and a corresponding increase in animal numbers.

Model rescue. A prostate line that grows poorly in immunodeficient mice is established in an immunodeficient rat background, allowing an efficacy study that was not feasible in the smaller species.

Considerations

Rat studies carry higher per-animal costs for housing, test article, and husbandry, and the choice of validated tumor models is narrower than in the mouse. The platform is therefore selected where a specific requirement justifies it, typically serial pharmacokinetics, a surgical model, or tissue yield, rather than as a default alternative to murine efficacy studies.

Species-specific protocol requirements

All procedures are conducted under active IACUC protocols. Because the species differs, protocols specify rat-appropriate housing and enrichment, blood sampling volume limits and recovery intervals, administration volume limits by route, anesthesia and analgesia regimens, and humane endpoints defined for the species rather than transferred from a mouse protocol. Cumulative sampling volume is tracked per animal across the study. GLP standards are applied where a study is formally designated as GLP.

Send indication, cell line, and sampling requirements, or request a quote.